For instance, Grandi et al demonstrated that administration of E. coli bEVs, engineered to express an epitope of the tumor-enriched antigen FAT1, generated tumor-targeting antibodies that protected mice from CT26 murine colon adenocarcinoma [137]. Here, FAT1 is linked to neoplasm.